glp 1 agonist schizophrenia Graphical presentation of the mechanism of action of GLP-1 receptor GLP-1 medications used to treat

Apart from WEGOVY, SAXENDA , another Novo Nordisk weight loss drug, is also approved in the US for obesity

CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031

5 This is in contrast to the typical call for most accidental overdoses involving children

These drugs are not magic and not without risks